---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-026017"
form_type: "8-K"
ticker: "SNDX"
cik: "0001395937"
company_name: "Syndax Pharmaceuticals Inc"
filed_at: "2022-12-05T23:59:59+00:00"
generated_at: "2026-06-21T09:29:02.760483+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Syndax appoints Steve Sabus as CCO; base $495K, option for 220K shares

## Summary
- Steve Sabus joins as Chief Commercial Officer effective December 5, 2022.
- Annual base salary of $495,000 with target bonus of 40% and option grant for 220,000 shares.
- Sabus previously CCO at Turning Point Therapeutics and 15-year Astellas veteran.
- Role focuses on commercial strategy for potential 2024 launches of revumenib and axatilimab.
- Severance includes 9-month base salary on termination w/o cause or good reason; 12-month + full vesting on change in control.

## SEC filing metadata
- accession: 0000950170-22-026017
- form_type: 8-K
- ticker: SNDX
- cik: 0001395937
- company_name: Syndax Pharmaceuticals Inc
- filed_at: 2022-12-05T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1395937/000095017022026017/0000950170-22-026017-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1395937/000095017022026017/sndx-20221201.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-026017
- JSON: https://secwatch.observer/filing/0000950170-22-026017.json
- Plain text: https://secwatch.observer/filing/0000950170-22-026017.txt

## Key facts
- Executive change
  Steve Sabus was appointed as Chief Commercial Officer at Syndax Pharmaceuticals Inc.
  - Action: appointed
  - Role: Chief Commercial Officer
  source text: On December 2, 2022, Syndax Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing that Steve Sabus will join the Company as Chief Commercial Officer, effective December 5, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1395937/000095017022026017/0000950170-22-026017-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.